A meta-analysis of 46 studies in the IBD population confirmed high seroconversion (96%) after completing a two-dose vaccine series, with lower serological response in those on anti-TNF therapies, and a subsequent decay of antibodies over time (28). The gene discussed is TNF; the disease is inflammatory bowel disease.